Lymphoma characteristics, conditioning regimens, side effects and outcome of the two female patients so far studied, after haematopoietic stem cell transplantation
| Variables | Patient 1 | Patient 2 | |
| Age (years) | 57 | 34 | |
| Diagnosis | NHL1-150 of the lung (large cells MALT1-150lymphoma) | Immunoblastic B lymphoma | |
| First line treatment | 6 cycles of F-MACHOP1-150 | VACOP-B1-150 followed by VIPE1-150 | |
| Conditioning regimens | ARA-C1-150 200 mg × 2/day × 4 | BCNU 300 mg/m2 | |
| VP161-150 200 mg × 2/day × 4 | Etoposide 800 mg/m2 | ||
| CTX1-150 1500 mg/day × 4 | Cytarabine 1600 mg/m2 | ||
| BCNU1-150 200 mg | Melphalan 140 mg/m2 | ||
| Reinfusion | MNC1-150 4.5 × 108/kg | MNC 2.42 × 108/kg | |
| CD34 0.9 × 106/kg | CD34 4.60 × 106/kg | ||
| CD3 not counted | CD3 37.03 × 106/kg | ||
| Days to PMN1-150 >1 × 109/l = 10 days | Days to PMN >10 × 109/l = 11 days | ||
| Days to Plt1-150 >20 × 103/l = 8 days | Days to Plt >50 × 103/l = 18 days | ||
| Sides effects/outcomes | Alive in complete continous lymphoma remission after 3 years | No remission of autoimmune disease | |
| No remission of autoimmune disease | Died 20 months after transplantation for Pneumocystis carinii pneumonia | ||
↵1-150 NHL = non-Hodgkin's lymphoma; MALT = mucosa associated lymphoid tissue; F-MACHOP: F = 5-fluorouracil, M = methotrexate, A = Adriamycin, C= cyclophosphamide, H = doxorubicin, O = Oncovin, P = prednisone; ARA-C = arabinoside-C; VP16 = etoposide; CTX = cyclophosphamide; BCNU = carmustine; MNC = mononuclear cells; PMN = polymorphonuclear cells; Plt = platelets; VACOP-B: V = Vepesid, A = Adriamycin, C = cyclophosphamide, O = vincristine, P = prednisone, B = bleomycin; VIPE: V = vinblastine, I = ifosfamide, P = prednisone, E = etoposide.